367 related articles for article (PubMed ID: 28086817)
1. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
[TBL] [Abstract][Full Text] [Related]
2. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK.
Matthews I; Duong M; Parsons VL; Nozad B; Qizilbash N; Patel Y; Guimicheva B
PLoS One; 2020; 15(2):e0229224. PubMed ID: 32097441
[TBL] [Abstract][Full Text] [Related]
3. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A
Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532
[TBL] [Abstract][Full Text] [Related]
4. Increasing incidence associated with herpes zoster infection in British Columbia, Canada.
Marra F; Chong M; Najafzadeh M
BMC Infect Dis; 2016 Oct; 16(1):589. PubMed ID: 27765026
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.
Gialloreti LE; Merito M; Pezzotti P; Naldi L; Gatti A; Beillat M; Serradell L; di Marzo R; Volpi A
BMC Infect Dis; 2010 Aug; 10():230. PubMed ID: 20682044
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of Herpes Zoster ("culebrilla") in Latin America.
Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD
Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595
[TBL] [Abstract][Full Text] [Related]
7. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.
Gauthier A; Breuer J; Carrington D; Martin M; Rémy V
Epidemiol Infect; 2009 Jan; 137(1):38-47. PubMed ID: 18466661
[TBL] [Abstract][Full Text] [Related]
10. Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia.
Friesen KJ; Falk J; Alessi-Severini S; Chateau D; Bugden S
J Pain Res; 2016; 9():543-50. PubMed ID: 27536159
[TBL] [Abstract][Full Text] [Related]
11. Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study.
Sato K; Adachi K; Nakamura H; Asano K; Watanabe A; Adachi R; Kiuchi M; Kobayashi K; Matsuki T; Kaise T; Gopala K; Holl K
J Dermatol; 2017 Apr; 44(4):414-422. PubMed ID: 27917531
[TBL] [Abstract][Full Text] [Related]
12. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
White RR; Lenhart G; Singhal PK; Insinga RP; Itzler RF; Pellissier JM; Segraves AW
Pharmacoeconomics; 2009; 27(9):781-92. PubMed ID: 19757871
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.
Curran D; Hunjan M; El Ghachi A; El-Hahi Y; Bianco V; Ferreira G
BMJ Open; 2019 Aug; 9(8):e023502. PubMed ID: 31462457
[TBL] [Abstract][Full Text] [Related]
14. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
[TBL] [Abstract][Full Text] [Related]
15. [Burden of herpes zoster and postherpetic neuralgia: Incidence, proportion, and associated costs in the French population aged 50 or over].
Mick G; Gallais JL; Simon F; Pinchinat S; Bloch K; Beillat M; Serradell L; Derrough T
Rev Epidemiol Sante Publique; 2010 Dec; 58(6):393-401. PubMed ID: 21094001
[TBL] [Abstract][Full Text] [Related]
16. Burden of herpes zoster and post-herpetic neuralgia in Sweden.
Nilsson J; Cassel T; Lindquist L
BMC Infect Dis; 2015 May; 15():215. PubMed ID: 26002038
[TBL] [Abstract][Full Text] [Related]
17. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition.
Harvey M; Prosser LA; Rose AM; Ortega-Sanchez IR; Harpaz R
Pain; 2020 Feb; 161(2):361-368. PubMed ID: 31599852
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain.
Cebrián-Cuenca AM; Díez-Domingo J; San-Martín-Rodríguez M; Puig-Barberá J; Navarro-Pérez J;
BMC Infect Dis; 2011 Nov; 11():302. PubMed ID: 22044665
[TBL] [Abstract][Full Text] [Related]
19. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
